| Overview |
| bs-9740R-RBITC |
| CNTD2 Polyclonal Antibody, RBITC Conjugated |
| IF(IHC-P) |
| Human |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CNTD2 |
| 141-240/307 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 79935 |
| CNTD2; CNTD 2; CNTD-2; Cyclin N terminal domain containing 2; Cyclin N terminal domain containing protein 2; FLJ13265; CNTD2_HUMAN. |
| CNTD2 (cyclin N-terminal domain containing 2) is a 155 amino acid protein that contains one cyclin N-terminal domain and is encoded by a gene that maps to human chromosome 19q13.2. Chromosome 19 consists of approximately 63 million bases and makes up over 2% of human genomic DNA. Chromosome 19 is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin superfamily members, including killer cell and leukocyte Ig-like receptors, various ICAMs, the CEACAM and PSG families, and Fc?receptors. Key genes for eye color and hair color also map to chromosome 19. Peutz-Jeghers syndrome, spinocerebellar ataxia type 6, the stroke disorder CADASIL, hypercholesterolemia and insulin-dependent diabetes have been linked to chromosome 19. Translocations with chromosome 19 and chromosome 14 can be seen in some lymphoproliferative disorders and typically involve the proto-oncogene Bcl-3. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz